N/A N=37 Does Glaucoma Cause Loss of Brain Function?
Glaucoma
Primary: Absolute Brain Volume (Size) — 3067; 2302 cubic millimeters (mm3)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028
N/A N=900 Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma · Diabetic Retinopathy · Refractive Errors
Primary: Percentage of Participants That Adhere to Referral Appointment — 80; 92 Participants
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 2 N=55 Safety and Efficacy of a Glaucoma Drug Delivery System
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Visual Acuity - Right Eye — 0.015; -0.044; -0.012 logMAR units
N/A N=15 Glaucoma Surgery Using the ViaLase Laser System
Glaucoma · Glaucoma, Open-Angle
Primary: Mean IOP — 12.7 mmHg
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
N/A N=161 How Has Glaucoma Affected Your Quality of Life?
Glaucoma · Quality of Life
Primary: Quality of Life With NEI VFQ-25 — 82.9; 82.7; 82.8; 83.0 units on a scale
Phase 2 N=70 Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
Phase 3 N=237 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure — 2.9; 1.6 mmHg
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
Phase 4 N=87 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Phase 4 N=86 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Nocturnal IOP at Week 4 — 24.2; 23.6; 18.6; 18.9 mmHg
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Phase 4 N=376 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)
N/A N=4 Health Coaching for Glaucoma Patients
Glaucoma
Primary: Glaucoma Medication Adherence — 72 percentage of adherence time
Phase 3 N=447 To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -5.30; -5.16; -6.92; -6.57 mmHG
Phase 3 N=44 Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract
Open-angle Glaucoma
Primary: Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications — 18; 4 participants
Phase 2 N=10 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Exfoliation Syndrome · Ocular Hypertension · Open Angle Glaucoma
Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg
Phase 3 N=495 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -4.25; -3.80; -4.22; -4.00 mmHG
Phase 2 N=241 A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Open-angle Glaucoma, Ocular Hypertension
Primary: Intraocular Pressure in the Study Eye at Month 3 — 18.8; 18.1; 19.7; 19.2 mmHg
Phase 2 N=112 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) — 24.54; 24.38; 24.29; -6.79 Millimeters of Mercury (mmHg)
N/A N=112 The Effects of Caffeinated Coffee on Intraocular Pressure
Primary Open Angle Glaucoma
Primary: Change in Intraocular Pressure at 60 Minutes — 1.51; 0.52 mm Hg
Phase 2 N=172 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.350; 25.318; 25.341; 24.650 Millimeters of Mercury (mmHg)
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Phase 4 N=263 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)